Bonevski, B., Rich, J., Skelton, E., Garfield, J., Baker, A., Segan, C., Gartner, C., Walker, N., Borland, R., Daglish, M., Dunlop, A., Oldmeadow, C., Bauld, L., Bullen, C., Ezard, N., McCrohan, R., Jacka, D., White, S., Lubman, D., & Manning, V. (2022). NEAT (NicotinE As Treatment) Trial: Protocol of a randomised controlled trial of vaporised nicotine products compared with nicotine replacement therapy following discharge from residential withdrawal services [10.1101/2022.05.15.22275118]. medRxiv, 2022.2005.2015.22275118. https://doi.org/10.1101/2022.05.15.22275118

Bonsaksen, T., Leung, J., Price, D., Ruffolo, M., Lamph, G., Kabelenga, I., Thygesen, H., & Geirdal, A. Ø. (2022). Self-Reported Long COVID in the General Population: Sociodemographic and Health Correlates in a Cross-National Sample [10.3390/life12060901]. Life, 12(6). https://doi.org/10.3390/life12060901

Bourke, S. C., Chapman, J., Jones, R., Brinckley, M. M., Thurber, K. A., Calabria, B., Doery, K., Olsen, A., & Lovett, R. (2022). Developing Aboriginal and Torres Strait Islander cultural indicators: an overview from Mayi Kuwayu, the National Study of Aboriginal and Torres Strait Islander Wellbeing [10.1186/s12939-022-01710-8]. International Journal for Equity in Health, 21(1). https://doi.org/10.1186/s12939-022-01710-8

Brener, L., Caruana, T., Broady, T., Cama, E., Ezard, N., Madden, A., & Treloar, C. (2022). Addressing injecting related risks among people who inject both opioids and stimulants: Findings from an Australian survey of people who inject drugs [10.1016/j.abrep.2021.100398]. Addictive Behaviors Reports, 15. https://doi.org/10.1016/j.abrep.2021.100398

Brien, R., Volpe, I., Grigg, J., Lyons, T., Hughes, C., McKinnon, G., Tzanetis, S., Crawford, S., Eade, A., Lee, N., & Barratt, M. J. (2022). Co-Designing High-Risk Drug Alerts for Health and Community Service Practitioners [10.21203/rs.3.rs-1479577/v1]. Research Square. https://doi.org/10.21203/rs.3.rs-1479577/v1

Brothers, T. D., Fraser, J., MacAdam, E., Morgan, B., & Webster, D. (2022). Uptake of slow-release oral morphine as opioid agonist treatment among hospitalised patients with opioid use disorder [10.1111/dar.13365]. Drug and Alcohol Review, 41(2), 430-434. https://doi.org/10.1111/dar.13365

Brothers, T. D., Lewer, D., Jones, N., Colledge-Frisby, S., Farrell, M., Hickman, M., Webster, D., Hayward, A., & Degenhardt, L. (2022). Opioid agonist treatment and risk of death or rehospitalization following injection drug use–associated bacterial and fungal infections: A cohort study in New South Wales, Australia [10.1371/journal.pmed.1004049]. PLoS Medicine, 19(7). https://doi.org/10.1371/journal.pmed.1004049

Brothers, T., Lewer, D., Colledge-Frisby, S., Jones, N., Bonn, M., Wheeler, A., Grebely, J., Farrell, M., Hayward, A., Hickman, M., & Degenhardt, L. (2022). Time periods of altered risk for severe injection drug use-associated skin and soft-tissue infections: protocol for a self-controlled case series in New South Wales, Australia, 2001-2018 [10.14324/000.rp.10157481]. https://doi.org/10.14324/000.rp.10157481

Bruno, C., Havard, A., Gillies, M., Coghill, D., Brett, J., Guastella, A., Pearson, S. A., & Zoega, H. (2022). Patterns of ADHD medicine use: A population-based study among Australian children and adults (2013-2020). 31, 71-71. https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000859084400136&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Bruno, R., & Wilson, Y. (2022). Tasmanian Drug Trends 2021: Key Findings from the Ecstasy and Related Drugs Reporting System (EDRS) Interviews [10.26190/x782-jj24].

Bruno, R., Wilson, Y., Greaves, R., & Briggs, M. (2022). Access to naloxone in Tasmania, 2014-2022 [10.26190/xajp-fs59].